The UK Medicines and Healthcare products Regulatory Agency (MHRA) has given the approval to the Skymount Medical for the purpose of commencing a clinical trial of the company’s oral treatments for the mild and moderate corona virus disease.
The human trial is going to be analysing the potential impact of a combination of two drugs along with a single antiviral drug against the placebo on the novel corona virus symptom serious and duration. The drug has been discovered using the artificial intelligence platform developed by the Louisiana State University known as ‘DeepDrug’, and the two combination if two drugs consists of a therapy for treating cancer and also an anti-parasitic agent.
Both the treatments have previously been obtaining the approval from the Food and Drug Administration (FDA) of the United States, and the US FDA has also been intending to address the load of the virus along with the inflammatory aspects of the novel corona virus, and the treatment has also demonstrated for the purpose of decreasing the viral load of the corona virus in the animal and cell studies.
The US FDA had also found for having no negative side effects of the therapy, and for the purpose of commencing the trial, and the company is also seeking the necessary Ethic Committee of the United Kingdom approval and also identifying the appropriate study centres.
Kishor Wasan, chief medical and scientific officer of Skymount Medical said, currently there are limited approval for the options of oral medication for the purpose for alleviating the corona virus symptoms.
Editor/Content Writer
